Immunome (NASDAQ:IMNM) Hits New 12-Month Low – Here’s What Happened

Immunome, Inc. (NASDAQ:IMNM) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $8.96 and last traded at $8.95, with a volume of 164836 shares traded. The stock had previously closed at $9.35.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Stephens assumed coverage on Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price target on the stock. Piper Sandler dropped their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Immunome in a research report on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $28.60.

Immunome Stock Down 1.9 %

The stock’s 50 day moving average price is $10.48 and its two-hundred day moving average price is $12.27. The stock has a market cap of $731.48 million, a price-to-earnings ratio of -1.13 and a beta of 1.90.

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall purchased 150,000 shares of Immunome stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several hedge funds have recently bought and sold shares of IMNM. BNP Paribas Financial Markets acquired a new position in shares of Immunome in the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS acquired a new position in shares of Immunome during the 4th quarter worth approximately $75,000. AlphaQuest LLC increased its stake in shares of Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after acquiring an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after acquiring an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC acquired a new position in shares of Immunome during the 4th quarter valued at about $95,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.